Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)
Abstract
Pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by patients. As a comparatively young discipline, its methods continue to evolve. Pharmacoeconomic analysis encompass cost-minimization, cost-utility, cost-benefit, and cost-effectiveness studies, providing essential information critical for optimization of pharmacotherapy, optimal healthcare resource allocation and drug development success.
About the Authors
O. V. Reshet'ko
State Budgetary Educational Institution V.I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
K. A. Lutsevich
State Budgetary Educational Institution V.I. Razumovsky Saratov State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Ritter JM. Money makes the world go round: the pervasiveness of pharmacoeconomics. Br J Clin Pharmacol. 2008; 66: 755–7.
2. Drummond M. Pharmacoeconomics: friend or foe? Ann Rheum Dis 2006; 65 (Suppl. III): iii44–iii47.
3. Pang F. Design, analysis and presentation of multinational economic studies. The need for guidance. Pharmacoeconomics 2002; 20: 75–90.
4. Petrov VI. Pharmacoepidemiology and pharmacoeconomics in Russia: the status of the problems and prospects of development. Klinicheskie issledovanija lekarstv v Rossii 2002; (1): 8-10 (in Russian).
5. Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010; 70: 350–355.
6. Mohan L, Kumari KM, Dikshit H, Biswas NR. Pharmacoeconomic exercise for undergraduate medical students. Int J Basic Clin Pharmacol. 2014; 3: 1099– 1100.
7. Kulkarni U, Deshmukh YA, Moghe VV, Rege N, Kate M. Introducing pharmacoeconomics (PE) in medical undergraduate curriculum. Afr J Pharm Pharmacol. 2010; 4: 27–30.
8. Babar ZU, Scahill S. Is there a role for pharmacoeconomics in developing countries? Pharmacoeconomics 2010; 28: 1069–74.
9. Singh J. International society for pharmacoeconomics and outcomes research. Indian J Pharmacol. 2006; 38: 376–7.
10. Lyles A. Recent trends in pharmacoeconomics: Needs and unmet needs. Eur J Pharm Sci 2008; 34: S7-S24.
11. Brazier J. Valuing health states for use in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 769–79.
12. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009; (12): 409–18.
13. Bodrogi J, Kalo Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010; 159: 1367–73.
14. Honig PK, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther. 2010; 87: 247–51.
15. Honig PK. Comparative effectiveness: The fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–6.
16. Krammer H. Pharmacoeconomic analyses – chance or 4th hurdle for innovative drugs. Wien Med Wochenschr 2006; 156: 606–11.
17. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (Suppl. 3): 11–29.
18. Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther. 2003; 28: 73–9.
19. Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost- minimization analysis – when are two therapies equal? J Clin Pharm Ther. 2003; 28: 145–50.
20. Lopert R, Lang DL, Hill S. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis – a technique for decision-making at the margin. J Clin Pharm Ther. 2003; 28: 243–9.
21. Brinsmead R, Hill S. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool? J Clin Pharm Ther. 2003; 28: 339–46.
22. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17: 501–13.
23. Khanna D, Tsevat J. Health-related Quality of Life – an introduction. Am J Managed Care 2007; 13: S218-S223.
24. Vemer P, Rutten-van Molken MPMH. Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. Eur J Health Econ. 2011; 12: 397–404.
25. Hughes D. An agenda for UK clinical pharmacology. Pharmacoeconomics. Br J Clin Pharmacol. 2012; 73: 968–72.
26. Hughes D, Reynolds DJ. Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees. Clin Med. 2009; 9: 490–2.
27. Rohilla A, Kumar A, Keshari R, et al. Pharmacoeconomics: An overview. International Journal of Research in Pharmacy and Chemistry 2013; 3: 64–8.
28. Waldman SA, Terzic A. Pharmacoeconomics in the era of individualized medicine. Clin Pharmacol Ther. 2008; 84: 179–82.
29. Iram M, Rani S, Hiremath R. Pharmacoeconomics: Need for the day. Indian J Pharm Pract. 2009; 2: 16–18.
30. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis GJ, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569–87.
31. Petrov VI, Sabanov AV. Pharmacoeconomic studies in the Russian health care system. Klinicheskie issledovanija lekarstv v Rossii 2004; (1): 7 (in Russian).
Review
For citations:
Reshet'ko O.V., Lutsevich K.A. Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review). The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):54-57. (In Russ.)
Views:
649
Email this article 